As part of our series focussing on available medicines in Australia, we have added a product review of use of larotrectinib in the treatment of adult and paediatric patients with locally advanced or metastatic solid TRK fusion-positive tumours.
This review discusses pharmacodynamics, indications and dosage, contraindications and a series of clinical studies featuring larotrectinib use. It also provides commentary and recommendations from Professor David Ziegler, a paediatric oncologist at the Kids Cancer Centre, Sydney Children’s Hospital, Randwick.
Please login below to download this issue (PDF)